US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Enzymatica signs another agreement in Asia with Evergreen for Hong Kong and Macau

Enzymatica has entered into a distribution agreement with healthcare company Evergreen Health Ltd for sales and marketing of ColdZyme® Mouth Spray in Hong Kong and Macau. This is the second contract after Japan in Enzymatica’s expansion into Asia. Product sales are expected to begin in 2019. Evergreen Health Ltd is part of Meiriki, a company that develops and sells various types of dietary supplements for the market in Hong Kong and Macau. Meiriki was founded in 1997 and has about 95 employees. The company, which sells products for vision, joint and cardiac problems, as well as products

New customer survey – ColdZyme prevents colds and reduces severity and duration among cold sufferers

In a recent consumer survey conducted by GfK, over 40% of customers state that they use ColdZyme preventively and if they nevertheless do catch a cold, almost 80 percent state that symptoms are milder and of shorter duration. In November GfK conducted a consumer survey on behalf of Enzymatica to study how ColdZyme customers perceive ColdZyme’s advantages and to assess the market in general. The survey included 100 customers in the common-cold category and 100 ColdZyme users in Sweden. The findings confirmed that most ColdZyme users either take ColdZyme preventively, or for early symptoms

Enzymatica gets full market coverage through wholesale agreement with Tamro

The biotech company Enzymatica has signed an agreement with the pharmacy wholesaler, Tamro, for the distribution and sale of, ColdZyme® Mouth Spray – against common cold, on the Swedish market. The agreement means that consumers will have even more opportunities to buy the product which will be on sale at pharmacy chains such as Cura and Lloyds. Enzymatica already has agreements with the majority of Sweden’s pharmacy chains. ”This is Enzymatica’s first agreement with any of the major wholesalers which supply both prescription and over-the-counter pharmaceutical products, as well as other

Enzymatica conducts a directed issue totalling SEK 19 million

The biotech company, Enzymatica, successfully completed a directed issue yesterday, raising around SEK 19 million before deducting issue expenses, under the authority of a resolution of the annual general meeting held on 6 May. The capital raised will be used primarily in the launch of the new treatment for the common cold, ColdZyme® Mouth Spray, on the Swedish market, and to finance the Company’s on-going research and product development work. At the annual general meeting held on 6 May, the Board was authorised, at its own discretion, to issue a maximum of 2,000,000 new shares with or

The COLDPREV study: ColdZyme Mouth Spray reduces both the viral load and the number of sick days with common cold in infected individuals, compared with placebo

Enzymatica today reports positive results from a clinical pilot study on 46 individuals performed at the Ear, Nose and Throat Clinic at Skåne University Hospital in Lund, Sweden. In individuals who were infected with the common cold virus, ColdZyme Mouth Spray reduced both the viral load and the number of sick days with a cold compared with placebo. “These are very interesting and promising results. The COLDPREV study shows statistically significant results with ColdZyme Mouth Spray in terms of reduction of the viral load in the throat and number of sick days with common cold in infected

Broad launch for ColdZyme® Mouth Spray, soon on Apoteket AB’s shelves

The biotech company Enzymatica has signed an agreement with Apoteket AB, Sweden’s largest pharmacy chain. From early September, Enzymatica’s cold treatment product, ColdZyme® Mouth Spray, will be on sale at Apoteket AB. As of early September, Enzymatica’s registered medical device product against the common cold, ColdZyme® Mouth Spray, will form part of the regular range stocked by Apoteket AB and will be available from outlets throughout Sweden. The launch coincides with the beginning of the usual cold season, i.e. the end of the summer holidays and the start of the school year. - We

Enzymatica signs agreement with Actavis for ColdZyme in the Nordic region

Enzymatica and the international pharmaceuticals company, Actavis, have signed a letter of intent on the sale of Enzymatica’s cold treatment product, ColdZyme® Mouth Spray, on the Nordic market. Under the agreement, ColdZyme Mouth Spray will be on sale in around 3,200 pharmacies and a large number of stores, including health food retailers, in the Nordic region. Under the letter of intent, Actavis ColdZyme Mouth spray will be licensed for distribution and sale in Sweden, Denmark, Finland, Norway and Iceland. Actavis anticipates launching ColdZyme for sale in Sweden during the second half

Enzymatica: ColdZyme® Mouth Spray – for treating the common cold – to be introduced by the Swedish Apotek Hjärtat pharmacy chain

Enzymatica has concluded an agreement with Apotek Hjärtat, Sweden’s second largest pharmacy chain. During February 2013, Enzymatica’s medical device product, ColdZyme® Mouth Spray, will be introduced as part of the product range at Apotek Hjärtat.“The agreement signed with the Apotek Hjärtat pharmacy chain serves as further confirmation of the interest in our products. The Apotek Hjärtat pharmacy chain is Sweden’s second largest pharmacy group, with some 270 pharmacies nationwide,” notes Michael Edelborg Christensen, CEO at Enzymatica. Enzymatica’s registered product, ColdZyme® Mouth

Enzymatica signs agreement with the Kronans Droghandel pharmacy chain

Enzymatica has concluded its first commercial agreement. This entails that Enzymatica’s medical device product, ColdZyme® Mouth Spray used against the common cold, will be on sale at the Kronans Droghandel pharmacies in early 2013. “The agreement is, of course, commercially important for us, since the pharmacy chains represent a significant factor in our launch strategy. It has been consistently our goal to launch among the pharmacy chains at the beginning of 2013 and thus it is extra gratifying to be able to deliveron schedule,” says Michael Edelborg Christensen, CEO at Enzymatica.

Enzymatica announces Fredrik Håkansson as its new CFO

Enzymatica announces the recruitment of Fredrik Håkansson as its new CFO, Fredrik will assume his position from 1[st] of December. Fredrik has extensive experience in finance and accounting and has held similar positions in several companies, most recently from Systemtext AB where he was CFO.- Fredrik has just the right background and competency. As we establish ourselves in the market, and sales are growing there will also be greater demands on our commercial and financial competency. Here will Fredrik be an asset and strength, said Michael Edelborg Christensen, CEO of Enzymatica AB.

Enzymatica inaugurates Scientific Advisory Board

Enzymatica has established a scientific advisory board. The board consists of four established and well-known scientists, with particular focus on enzyme technology and infectious diseases. The purpose of the Scientific Advisory Board is in general to assist and advice Enzymaticas board of management in research-related issues and specifically to evaluate and advice on future clinical research and pipeline development.- It is part of our strategy to deliver and develop products with strong scientific support. We have therefore decided to establish a renowned Scientific Advisory Board to

Enzymatica’s ColdZyme® Mouth Spray against common cold is registered with the Swedish Medical Product Agency

Enzymatica AB (publ) has registered ColdZyme ® Mouth Spray with the Swedish Medical Product Agency as a medical device, Class I. The product is intended for the prevention and treatment of common cold, it may also reduce the duration, if used in the early stages of common cold. The ColdZyme® Mouth Spray is based on an enzyme derived from the deep-sea cod that has been shown to have very good therapeutic characteristics. Negotiations are ongoing with the major pharmacy chains and wholesalers in Sweden for the upcoming large-scale launches in Sweden and the other Nordic countries. · The

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe